Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tricuspid Valve Insufficiency | 7 | 2026 | 23 | 2.510 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2026 | 171 | 1.980 |
Why?
|
| Tricuspid Valve | 7 | 2026 | 28 | 0.800 |
Why?
|
| Partial Thromboplastin Time | 1 | 2020 | 9 | 0.670 |
Why?
|
| Factor Xa | 1 | 2020 | 5 | 0.670 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 36 | 0.650 |
Why?
|
| Blood Coagulation | 1 | 2020 | 41 | 0.650 |
Why?
|
| Heparin | 1 | 2020 | 118 | 0.620 |
Why?
|
| Treatment Outcome | 8 | 2023 | 5775 | 0.360 |
Why?
|
| Cardiac Catheterization | 5 | 2026 | 292 | 0.340 |
Why?
|
| Electrocardiography | 2 | 2020 | 553 | 0.260 |
Why?
|
| Severity of Illness Index | 4 | 2023 | 1557 | 0.240 |
Why?
|
| Ventricular Remodeling | 2 | 2023 | 90 | 0.240 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6831 | 0.220 |
Why?
|
| Histone Acetyltransferases | 1 | 2024 | 59 | 0.210 |
Why?
|
| RNA, Double-Stranded | 1 | 2024 | 112 | 0.210 |
Why?
|
| Interferons | 1 | 2024 | 73 | 0.200 |
Why?
|
| Heart Failure | 2 | 2023 | 948 | 0.200 |
Why?
|
| Chromatin | 2 | 2018 | 641 | 0.200 |
Why?
|
| Research Design | 1 | 2026 | 585 | 0.190 |
Why?
|
| Cytidine Deaminase | 1 | 2023 | 86 | 0.190 |
Why?
|
| Stem Cells | 1 | 2024 | 275 | 0.180 |
Why?
|
| Humans | 18 | 2026 | 64936 | 0.180 |
Why?
|
| Mice, Knockout | 2 | 2024 | 2154 | 0.170 |
Why?
|
| Data Warehousing | 1 | 2020 | 7 | 0.170 |
Why?
|
| RNA Stability | 1 | 2021 | 104 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1104 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 112 | 0.170 |
Why?
|
| Shock, Cardiogenic | 1 | 2022 | 108 | 0.170 |
Why?
|
| Troponin T | 1 | 2020 | 24 | 0.160 |
Why?
|
| Aged | 5 | 2023 | 14881 | 0.160 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2021 | 153 | 0.160 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 17 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 176 | 0.150 |
Why?
|
| Female | 10 | 2023 | 33876 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2020 | 202 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 133 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 161 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 214 | 0.150 |
Why?
|
| Heart Rate | 1 | 2020 | 331 | 0.140 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 51 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 309 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 46 | 0.140 |
Why?
|
| Male | 8 | 2023 | 30918 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2020 | 222 | 0.140 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2018 | 119 | 0.140 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2017 | 13 | 0.140 |
Why?
|
| Iron-Binding Proteins | 1 | 2017 | 11 | 0.140 |
Why?
|
| Friedreich Ataxia | 1 | 2017 | 7 | 0.140 |
Why?
|
| Patient Admission | 1 | 2019 | 197 | 0.130 |
Why?
|
| Incidence | 1 | 2022 | 1414 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 304 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2020 | 387 | 0.130 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 197 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2020 | 2093 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 702 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 67 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 408 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 588 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2024 | 3154 | 0.100 |
Why?
|
| Middle Aged | 5 | 2021 | 18173 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1132 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 871 | 0.090 |
Why?
|
| New York City | 2 | 2021 | 93 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 203 | 0.080 |
Why?
|
| Comorbidity | 2 | 2023 | 1115 | 0.070 |
Why?
|
| Endpoint Determination | 1 | 2026 | 27 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 1775 | 0.060 |
Why?
|
| Proteins | 2 | 2023 | 764 | 0.060 |
Why?
|
| Cell Self Renewal | 1 | 2024 | 13 | 0.050 |
Why?
|
| Intestines | 1 | 2024 | 178 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 2483 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2023 | 59 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2023 | 88 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2023 | 129 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 250 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 217 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2023 | 5582 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 426 | 0.040 |
Why?
|
| Mitochondria | 1 | 2024 | 402 | 0.040 |
Why?
|
| India | 1 | 2020 | 164 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 189 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 5410 | 0.040 |
Why?
|
| Animals | 3 | 2024 | 21345 | 0.040 |
Why?
|
| Mice | 2 | 2024 | 11114 | 0.040 |
Why?
|
| PAX5 Transcription Factor | 1 | 2018 | 13 | 0.040 |
Why?
|
| Azepines | 1 | 2018 | 22 | 0.040 |
Why?
|
| Boston | 1 | 2019 | 257 | 0.040 |
Why?
|
| Acetylation | 1 | 2018 | 121 | 0.040 |
Why?
|
| Triazoles | 1 | 2018 | 63 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2019 | 147 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2017 | 86 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1270 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 511 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1035 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 314 | 0.030 |
Why?
|
| Nicaragua | 1 | 2016 | 17 | 0.030 |
Why?
|
| Urinalysis | 1 | 2016 | 37 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 24 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2021 | 874 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1095 | 0.030 |
Why?
|
| Creatinine | 1 | 2016 | 135 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 178 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 670 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 445 | 0.030 |
Why?
|
| Histones | 1 | 2018 | 494 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 1473 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 2659 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 127 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 430 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1560 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3472 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1642 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 1386 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 907 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 2366 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1276 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 1437 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 3757 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 17286 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2610 | 0.020 |
Why?
|